Nomura Asset Management Co. Ltd. grew its holdings in argenex SE (NASDAQ:ARGX – Free Report) by 262.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 49,358 shares of the company’s stock after purchasing an additional 35,758 shares during the period. Nomura Asset Management Co. Ltd. owned approximately 0.08% of argenex worth $41,508,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently modified their holdings of ARGX. Oppenheimer & Co. Inc. boosted its holdings in shares of argenex by 2.8% during the 4th quarter. Oppenheimer & Co. Inc. now owns 442 shares of the company’s stock valued at $372,000 after acquiring an additional 12 shares in the last quarter. Valeo Financial Advisors LLC boosted its holdings in shares of argenex by 0.9% during the 4th quarter. Valeo Financial Advisors LLC now owns 1,372 shares of the company’s stock valued at $1,153,000 after acquiring an additional 12 shares in the last quarter. Sound View Wealth Advisors Group LLC boosted its holdings in shares of argenex by 3.4% during the 3rd quarter. Sound View Wealth Advisors Group LLC now owns 396 shares of the company’s stock valued at $292,000 after acquiring an additional 13 shares in the last quarter. Allworth Financial LP boosted its holdings in shares of argenex by 12.7% during the 4th quarter. Allworth Financial LP now owns 115 shares of the company’s stock valued at $97,000 after acquiring an additional 13 shares in the last quarter. Finally, Portside Wealth Group LLC boosted its holdings in shares of argenex by 2.8% during the 3rd quarter. Portside Wealth Group LLC now owns 583 shares of the company’s stock valued at $430,000 after acquiring an additional 16 shares in the last quarter. Institutional investors own 60.32% of the company’s stock.
argenex Stock Performance
ARGX stock opened at $835.99 on Monday. The stock’s 50 day simple moving average is $779.30 and its 200 day simple moving average is $814.88. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.62. The company has a market cap of $51.99 billion, a P/E ratio of 37.22, a price-to-earnings-growth ratio of 1.32 and a beta of 0.47.
Analyst Upgrades and Downgrades
Several research analysts have commented on the company. HC Wainwright lifted their target price on argenex from $915.00 to $940.00 and gave the stock a “buy” rating in a report on Friday, February 27th. Oppenheimer cut their target price on argenex from $1,060.00 to $1,014.00 and set an “outperform” rating on the stock in a report on Thursday, April 2nd. Citizens Jmp lifted their target price on argenex from $925.00 to $944.00 and gave the stock a “market outperform” rating in a report on Friday, February 27th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of argenex in a report on Monday, April 20th. Finally, Zacks Research raised argenex from a “strong sell” rating to a “hold” rating in a report on Friday, February 20th. Two analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $1,017.78.
Get Our Latest Stock Report on argenex
argenex Profile
argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.
The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.
Read More
- Five stocks we like better than argenex
- These 3 CLO ETFs Target a Niche Corner of the Fixed-Income Market
- 3 Ways to Play the Data Center Land Grab
- The Smarter Way to Invest in AI Without Taking Extreme Risk
- 3 Dividend Kings That Earn Their Crown Every Quarter
Want to see what other hedge funds are holding ARGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for argenex SE (NASDAQ:ARGX – Free Report).
Receive News & Ratings for argenex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenex and related companies with MarketBeat.com's FREE daily email newsletter.
